T he outbreak of Middle East respiratory syndrome coronavirus (MERS-CoV) infections poses a threat to public health worldwide. MERS-CoV causes a severe acute respiratory syndrome (SARS)-like human respiratory disease; the infections emerged in Saudi Arabia in 2012 and subsequently spread to eight other countries in the Middle East and to Europe (1, 2) . As of 6 October 2013, it has caused 136 confirmed human infections, including 58 deaths, a case fatality rate of 43% (http://www.cdc.gov/coronavir us/mers/). Although the predicted pandemic potential of MERS is low (3) , an increase with further evolution of MERS-CoV in nature is of concern. To date, no effective treatment for infected individuals has been reported, indicating the need for development of effective therapeutic approaches.
Cyclic AMP (cAMP) is a regulator of many biological processes in many life forms, including microorganisms, plants, animals, and humans (4, 5) . Intracellular levels of cAMP are tightly regulated by many cell type-specific isoforms of adenyl cyclase (AC) and phosphodiesterase (PDE), a family of enzymes that inhibit cAMP signaling by degrading intracellular cAMP (6, 7) . While the impact of cAMP on diverse cellular functions is complex, an elevated expression of intracellular cAMP generally suppresses host antimicrobial defense (8) . A critical role for cAMP signaling in regulating host defense mechanisms is underscored by the fact that many pathogens, including viruses, establish infection in permissive hosts by having evolved strategies targeting the adenosine-cAMP axis to modulate the levels of intracellular cAMP (9) .
Protein kinase A (PKA) and exchange proteins directly activated by cAMP (Epac) are two primary intracellular cAMP binding proteins that mediate most of the cAMP-regulated physiological functions (10) (11) (12) (13) (14) (15) . While most of the cAMP-mediated biological processes are classically associated with PKA, recent studies have indicated that Epac, acting either alone or in concert with PKA, regulates diverse biological responses by activating several members of the Ras superfamily, in particular Rap GTPase, via GTP loading (16) . Epac exists as two isoforms, Epac-1 and Epac-2, which are coded by different genes. Alternative splicing adds to the complexity of the differential expression profile of Epac both on the mRNA and protein levels (17) . Specifically, Epac-1 is abundantly expressed in the heart, kidney, blood vessels, adipose tissue, central nervous system (CNS), ovary, uterus, and various myeloid and lymphoid cells, whereas Epac-2 sliced variants are mostly expressed in the CNS, adrenal gland, and pancreas (16) . Although intracellular cAMP plays a role in regulating host antimicrobial responses, its effect on MERS-CoV infection in permissive cells has not been previously investigated.
We have recently shown that human bronchial epithelial Calu-3 cells are highly permissive to MERS-CoV, resulting in acute and profound apoptosis (18) . Since PKA and Epac serve as key mediators of cAMP signaling, to investigate if cAMP signaling participates in regulating the infection of virus, we pretreated Calu-3 cells with either H89 (LC Laboratories), a PKA-specific inhibitor (19) , an Epac-specific inhibitor (ESI-09) (13, 20) , or dimethyl sulfoxide (DMSO) (as the carrier control) for 2 h before challenging the cells with MERS-CoV at a multiplicity of infection (MOI) of 0.1. Subsequent effects on infected cells were assessed by monitoring the formation of cytopathic effects (CPE) and the yields of infectious progeny virus at 24 h postinfection (p.i.). We found that prior treatment with ESI-09, but not H89, attenuated CPE formation (data not shown) and significantly reduced viral yields (P Ͻ 0.001) ( Fig. 1A) . To determine if ESI-09-mediated inhibition of MERS-CoV replication is limited to Calu-3 cells, we performed the same experiment using Vero E6 cells. Figure 1B indicates that the ability of ESI-09 treatment to restrict MERS-CoV infection was cell type independent, as results were similar with Vero E6 cells. We also noted that a significant reduction in virus yield occurred when cells were treated with ESI-09 at the concentrations between 5 and 40 M in Calu-3 cells (Fig. 1C ). As shown in Fig. 1D , the concentration of ESI-09 required for causing 50% inhibition of cell survival (CC 50 ) was greater than 50 M for both Calu-3 and Vero E6 cells, based on the lactate dehydrogenase (LDH)-based cytotoxicity assay (Promega), suggesting that the anti-MERS-CoV growth inhibition imposed by ESI-09 treatment at the concentration of 10 M was not because of drug cytotoxicity. To further investigate the effect of ESI-09 on MERS-CoV replication, Calu-3 cells grown in 8-well chamber slides (Nunc Lab-Tek) were treated with 10 M H89, ESI-09, or DMSO for 2 h prior to challenge with virus at an MOI of 0.1. The effect of ESI-09 was assessed by determining the yields of infectious virus and the ex-pressions of CD26, the receptor of MERS-CoV (21) , and virusspecific antigens at 24 h p.i. by the standard indirect immunofluorescence (IIF) staining. Stained specimens were analyzed with an inverted UV microscopy (Olympus 1X51). As shown in Fig. 2A , DMSO control and H89 treatment did not protect against MERS-CoV infection, as shown by the extensive CPE (i.e., detachment of monolayer) and readily detectable viral antigen (red). In contrast, Calu-3 cells treated with ESI-09 were almost fully protected, as indicated by unnoticeable CPE and minimal expression of viral antigen. This capacity of ESI-09 to protect cells against MERS-CoV infection was consistent with the amount of infectious progeny viruses detected ( Fig. 2B ). To evaluate whether the anti-MERS-CoV activity of ESI-09 could be extended to include anti-SARS-CoV activity, we performed experiments using the same treatment and infection strategy as described for MERS-CoV. Prior ESI-09, but not H89, treatment was also effective in protect- The lactate dehydrogenase (LDH)-based cytotoxicity assay (Promega) was used to evaluate the drug's cytotoxic potential. Briefly, confluent Calu-3 and Vero E6 cells grown in 6-well plates were incubated with the indicated concentrations of ESI-09 for 24 h before LDH released into the culture medium was assessed. Cells incubated with 50 M DMSO were included as controls. ***, P Ͻ 0.001, 1-way or 2-way analysis of variance (ANOVA). A representative from at least two independently conducted experiments of each type is presented.
ing cell cultures against SARS-CoV, resulting in nearly a 4-log 10 reduction in viral titers (Fig. 2C ).
As the extracellular domain of CD26 can be released into the circulation as soluble CD26 (22, 23) , we investigated whether ESI-09 treatment might reduce surface expression of CD26, thereby reducing MERS-CoV binding and subsequent virus replication. For this, we compared the effect of DMSO versus ESI-09 treatment, at 10 M for 2 h, on CD26 expression in Calu-3 cells by both Western blotting and IIF. Whereas the total amount of CD26 was not affected by ESI-09 treatment (Fig. 3A) , the pattern of CD26 expression on the membrane of Calu-3 cells was changed with ESI-09 treatment (Fig. 3B) . In contrast to the relatively diffuse expression pattern in DMSO-treated cells, the expression of CD26 was rearranged, becoming more concentrated at the cell membrane in response to ESI-09 treatment. We also investigated whether such an altered pattern of CD26 expression would affect viral binding to Calu-3 cells. For this study, we incubated untreated or DMSO-, H89-, or ESI-09-treated Calu-3 cells with an equal amount of infectious MERS-CoV (MOI of 20) in an ice bath for 2 h; cells were then washed thoroughly with ice-cold phosphate-buffered saline (PBS) to remove unbound viruses and submitted to one cycle of freeze (Ϫ80°C)-thaw in 100 l of minimal essential medium (MEM)-2% fetal calf serum (FCS) medium to maximally retrieve membrane-bound viral particles for titrations. As shown in Fig. 3C , neither H89 nor ESI-09 treatment adversely influenced MERS-CoV binding to Calu-3 cells, compared to untreated or DMSO-treated cells. To identify which stage(s) of a virus's life cycle downstream of the binding/adsorption might be affected by ESI-09 treatment, Calu-3 cells grown in 12-well plates were infected with live or gamma (␥)-inactivated (cobalt-60, 5 megarads) MERS-CoV (MOI ϭ 5) for 1 h at 4°C, followed by ESI-09 or DMSO treatment (10 M), before harvesting total RNA and cell lysates at the indicated time points p.i. for determining the kinetics of virus RNA replication by using a real-time (RT) reverse transcription touch thermal cycler (Bio-Rad) and Western blot analyses. For quantifying viral RNA replication by RT-PCR, we targeted a region upstream of the envelope (E) gene (upE), as described previously (24) , and the GAPDH gene as the internal control. As shown in Fig. 3D , ESI-09 treatment significantly inhibited genomic replication of virus, starting at 6 h, reaching the maximum at 8 h, and remained inhibitory at 12 h p.i. As anticipated, viral RNA replication was not detected in cells challenged with ␥-inactivated virus (data not shown). These ESI-09-mediated inhibitory kinetics of viral RNA replication was consistent with the expression of spike-surface glycoproteins (S) and the nucleocapsid (N) protein as revealed by Western blot analyses (Fig.  3E) , thereby suggesting that inhibiting viral RNA replication and protein synthesis are likely antiviral mechanisms of ESI-09. Taken together, these results suggested that the cAMP-Epac, but not cAMP-PKA, signaling axis plays a role in the regulation of MERS-CoV replication in permissive cells.
To more definitely demonstrate that Epac proteins are important for sustaining viral replication, we established Epac-1 gene knockdown (KD) Calu-3 cells by using the short hairpin RNA (shRNA) lentiviral transduction system (Sigma-Aldrich) (25) . These KD cells enabled us to examine the effect Epac-1 might have in regulating the replication of both MERS-CoV and SARS-CoV and to validate the results attributed to the pharmacological inhibitor. As shown in Fig. 4A , Epac-1 expression was reduced by ϳ50% in KD Calu-3 cells compared to that in the control KD cells.
To evaluate whether such a moderate reduction in Epac-1 expression could have an effect on viral replication similar to that of the ESI-09 treatment, we infected both control and Epac-1 KD cells with either MERS-CoV or SARS-CoV (MOI of 0.1) for 24 h before assessing virus yields. As shown in Fig. 4B , reducing Epac-1 expression by ϳ50% was sufficient to significantly reduce the replication of MERS-CoV and SARS-CoV.
While the activity state of Epac, a multidomain mediator of cAMP signaling, is determined by its allosteric interaction with cAMP (16) , an increased transcriptional expression of Epac gene has been demonstrated in mice suffered from either myocardial hypertrophy or neointima formation induced by vascular injury (26, 27) . Since Epac appears to play a previously unidentified role in supporting viral replication, we determined whether its expression could be modified in response to acute MERS-CoV infection. Briefly, MERS-CoV-infected Calu-3 cells (MOI ϭ 5) grown in 12-well plates were treated with DMSO or ESI-09 (10 M) for the indicated time periods before harvesting supernatants and extracting cellular lysates for assessing virus titers and Epac protein expression. As anticipated, early ESI-09 treatment resulted in profound reduction of virus titers, especially at both 12 and 22 h p.i. (data not shown). Western blot analyses using mouse anti-Epac (Santa Cruz) or rabbit anti-GAPDH antibody (Cell Signaling Technology) in combination of anti-mouse IgG-horseradish peroxidase (HRP) (Biolab) or anti-rabbit IgG-HRP (Cell Signaling Technology) revealed that neither ESI-09 treatment nor MERS-CoV infection over time could significantly modulate the level of Epac protein expression ( Fig. 5A ). We also determined if the expression of Epac can be colocalized with intracellular virus, in which Calu-3 cells grown in chamber slides were infected with recombinant MERS-CoV (rMERS-CoV) expressing red fluorescence protein (RFP) at 4°C for 1 h (28), followed by treatment with either DMSO or ESI-09 for the indicated time periods before assessing the expression of Epac and MERS-CoV-RFP by IF. Consistent with Western blot results, the expression pattern and intensity of Epac (Fig. 5B , green dots, arrows) in Calu-3 cells was not affected by either MERS-CoV infection or ESI-09 treatment. Additionally, its expression was not strictly colocalized with intracellular viruses either (Fig. 5B, red, arrowheads) .
While it is clear that prior ESI-09 treatment was effective in restricting MERS-CoV and SARS-CoV replication without compromising viral binding, we further evaluated whether the antiviral effect provided by ESI-09 could be attributed to a virucidal effect. For this test, we incubated an equal volume of SARS-CoV or MERS-CoV with MEM-2% FCS (M-2), DMSO (10 M), or ESI-09 (10 M) at 37°C for 2 h before determining their effect on viral yields in Vero E6 cells. We found that neither DMSO nor ESI-09 treatment had any noticeable direct effect on the resulting viral yields (Fig. 6A) . To investigate if the antiviral effect of ESI-09 required its continuing presence in the culture system, we treated duplicate sets of Calu-3 cell cultures with DMSO vehicle or 10 M ESI-09 for 2 h. One set was replenished with DMSO and ESI-09 after MERS-CoV challenge (MOI of 0.1), whereas the other set received M-2 medium without the additives. As shown in Fig. 6B , the ability of ESI-09 to inhibit viral replication appears to be reversible, as cells first treated with ESI-09 and replenished with M-2 medium without ESI-09 showed no evidence of virus inhibition. Finally, to determine if treatment of cells prior to challenge is a prerequisite for ESI-09's antiviral effect, we examined the effect of adding ESI-09 at various times after initiating virus infection. Briefly, Calu-3 cells were treated with ESI-09 at the indicated time points ( Fig. 6C and D) , where 0 h is defined as the time of viral challenge. Cell culture supernatants were harvested for assessing protective efficacy at either 38 h (MOI of 0.1) or 24 h (MOI of 5) postchallenge. Not only was the prechallenge treatment unnecessary for protection, but treating infected cells (MOI of 0.1) with ESI-09 as late as 16 or 20 h (Fig. 6C ) or treating 12 h postchallenge for those infected with an MOI of 5 (Fig. 6D ) was effective in reducing viral replication, thereby suggesting the treatment late in infection could be beneficial. The effectiveness of such a delayed ESI-09 treatment in plunging the yields of virus in Calu-3 cells suggests that this antiviral drug might affect a late event(s) of the virus replication strategy, such as assembly and/or release, in addition to inhibiting synthesis of viral proteins and RNA replication ( Fig. 3D and E) .
In summary, in these initial studies of the potential linkage of the cAMP signaling pathway and MERS-CoV infection, we identified a previously unknown function of Epac-1 protein in regulating the replication of both MERS-CoV and SARS-CoV in a cell type-independent manner. These conclusions were based on the usage of both an Epac-specific inhibitor (ESI-09) and Epac-1 KD cells and Calu-3 and Vero E6 tissue cultures. While the exact mechanism of the cAMP-Epac axis in the cellular events of viral replication remains to be fully described, we found that ESI-09 exerts an antiviral effect when used at a nontoxic concentration. In addition, it does so, not only without the need for treatment prior to infection, but also with an extended therapeutic window. Incidentally, adenosine and its analogs have been successfully investi- gated as potent inhibitors of the replication of hepatitis C virus, vaccinia virus, HIV-1, dengue virus, and other flaviviruses (29) (30) (31) (32) . The dual role of CD26 as the MERS-CoV receptor and an adenosine deaminase (ADA)-anchoring protein (33) (34) (35) (36) provides a potential linkage between MERS-CoV infection and cAMP signaling. However, the potential role of the cAMP axis in the host response to MERS-CoV has yet to be studied. Nevertheless, these findings indicate that further characterization and development of ESI-09 and its analogs as a new class of antiviral agents may represent a strategy for combating MERS-CoV and possibly other emerging and reemerging virus infections.
